Dr. Golijanin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2 Dudley St
Ste 185
Providence, RI 02905Phone+1 401-421-0710Fax+1 401-444-6947
Summary
- Dragan Golijanin, MD, is a director of the Minimally Invasive Urology Institute and director of Genitourinary Oncology at The Miriam Hospital. He also serves as an associate professor of surgery (urology) at The Warren Alpert Medical School of Brown University. His areas of expertise include prostate cancer, kidney cancer, bladder cancer and testicular cancer. Golijanin is board certified in urology.
Golijanin earned his medical degree at the University of Belgrade. He completed residencies at the University of Rochester School of Medicine, University Clinical Center in Belgrade and Hadassah Medical Center. He completed fellowships in urologic oncology at Memorial Sloan-Kettering Cancer Center and Cornell University and Hadassah Medical Center, and was the first to publish on near-infrared real-time imaging in open laparoscopic and robotic surgery.
Education & Training
- University of RochesterResidency, Urology, 2004 - 2009
- University of Rochester Medical CenterInternship, Transitional Year, 2003 - 2004
- University of RochesterInternship, Surgery, 2003 - 2004
- Memorial Sloan Kettering Cancer CenterFellowship, Urologic Surgical Oncology, 2000 - 2003
- Hadassah Medical CenterUrology Residency, 1995 - 1999
- Department of Urology Hadassah Medical CenterUrologic Oncology Fellowship, Urologic Oncology Fellowship, 1993 - 1995
- University of Belgrade Faculty of MedicineClass of 1984
Certifications & Licensure
- RI State Medical License 2011 - 2026
- NY State Medical License 2006 - 2013
- American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013
Publications & Presentations
PubMed
- 2 citationsTargeting Bladder Urothelial Carcinoma with pHLIP-ICG and Inhibition of Urothelial Cancer Cell Proliferation by pHLIP-amanitin.Anna Moshnikova, Borivoj Golijanin, Ali Amin, Joshua Doyle, Ohad Kott
Frontiers in Urology. 2022-01-01 - 66 citationsThe role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta-analysis.Bimal Bhindi, Christopher J.D. Wallis, Stephen A. Boorjian, R. Houston Thompson, Ann M. Farrell
BJU International. 2018-05-01 - 73 citationsBladder cancer as a prognostic factor for upper tract transitional cell carcinoma.Michael Mullerad, Paul Russo, Dragan Golijanin, Hui N.I. Chen, Harold Tsai
The Journal of Urology. 2004-12-01
Journal Articles
- The Association of Lymph Node Dissection with 30-Day Perioperative Morbidity Among Men Undergoing Minimally Invasive Radical Prostatectomy: Analysis of the National Su...Anthony Mega, Joseph 2nd Renzulli, Gyan Pareek, Boris Gershman, Ali Amin, Dragan Golijanin, Nature
Press Mentions
- Molecular Delivery System Developed at URI Shows Promise Against Bladder CancerSeptember 19th, 2022
- New Registry Aims to Find Out Why RI Has Highest Incidence of Bladder Cancer Per CapitaNovember 5th, 2020
- Miriam First in New England to Do Completely Laparoscopic Robotic-Assisted Surgery for Bladder CancerOctober 12th, 2016
- Join now to see all
Other Languages
- French, Hebrew, Croatian, Serbian, Bosnian
External Links
- Minimally Invasive Urology Institute at The Miriam Hospitalhttps://www.lifespan.org/centers-services/minimally-invasive-urology-institute
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: